TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004Vol.30 No.39
TCL Archive Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual. October 15, 2004Vol.30 No.39
TCL Archive Hope for FDA authority over tobacco products dies in Congress. October 15, 2004Vol.30 No.39
TCL Archive Patients urge Medicare to allow an open formulary for cancer treatment. October 15, 2004Vol.30 No.39
TCL Archive Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service. October 15, 2004Vol.30 No.39
TCL Archive New guidelines for Cancer Center Support Grants will enable centers to apply for salary support for clinical investigators. October 08, 2004Vol.30 No.38
TCL Archive New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB. October 08, 2004Vol.30 No.38
TCL Archive Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products. October 08, 2004Vol.30 No.38
